The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Breast Cancer

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CBC.2008.n.065PMID 19073509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.

  2007cited by this paper
• Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

  2007cited by this paper
• Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

  2007cited by this paper
• Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

  2007cited by this paper
• Endometrial effects of exemestane compared to tamoxifen within the TEAM trial: Results of a prospective randomized study

  2007cited by this paper
• Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

  2006cited by this paper
• Aromatase inhibitors and bone health in women with breast cancer.

  2006cited by this paper
• Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

  2005cited by this paper
• The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer

  2005cited by this paper
• Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

  2005cited by this paper
• The Effect of Exemestane on the Lipidemic Profile of Postmenopausal Early Breast Cancer Patients: Preliminary Results of the TEAM Greek Sub-study

  2005cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004cited by this paper
• Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

  2004cited by this paper
• American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2000cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper

• Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis

  2021cites this paper
• Adherence to bone health guidelines in patients with hormone receptor-positive early breast cancer: Status and clinical impact in a Swiss cohort experience

  2021cites this paper
• Recommandations françaises de stratégies thérapeutiques pour la prévention et le traitement de l’ostéoporose induite par les traitements adjuvants du cancer du sein

  2019cites this paper
• French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies.

  2019cites this paper
• A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.

  2016cites this paper
• Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer.

  2014cites this paper
• Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

  2014cites this paper
• Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole

  2013influential citation
• Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.

  2012cites this paper
• Exemestane

  2012cites this paper
• Osteoporosis and aromatase inhibitors: experience and future prospects.

  2012cites this paper
• Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients

  2011cites this paper
• The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies

  2011influential citation
• Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

  2011cites this paper
• Clinical review: Effect of endocrine therapies on bone in breast cancer patients.

  2011cites this paper
• Management of bone disease in patients undergoing hormonal therapy for breast cancer.

  2011cites this paper
• Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy

  2011influential citation
• 42 – Bone health and prevention of treatment-induced osteoporosis in oncology

  2011cites this paper
• Aging and osteoporosis in breast and prostate cancer

  2011cites this paper
• Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane.

  2010cites this paper
• Bone Continuum of Cancer

  2010cites this paper
• Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.

  2009cites this paper
• Bone health maintenance in survivors of breast and prostate cancer

  2009cites this paper
• 2008 Publications of the Baylor Health Care System Medical and Scientific Staff

  2009cites this paper
• Early breast and prostate cancer and clinical outcomes (fracture).

  2009cites this paper
• Sex hormones and related compounds, including hormonal contraceptives

  2007cites this paper